PhD Kamil Przyborowski is the third laureate of the last edition of the SONATA competition, announced by the National Center of Science in Krakow on behalf of the Jagiellonian Centre for Experimental Therapeutics (JCET). Doctor Przyborowski will implement a project entitled Inhibition of protein disulfide isomerases as a strategy for reduction of prothrombotic state in atherosclerosis; therapeutic implications.

Antiplatelet treatment is a gold standard to combat atherothrombosis. Despite advances in antithrombotic therapy the cardiovascular diseases (CVDs), including myocardial infarction and stroke, are still the leading causes of death worldwide. Therefore, development of more effective and safe antithrombotic agents targeting new mechanisms is crucial. Protein disulfide isomerase (PDI) A1, PDIA3 or PDIA6 released from platelets and endothelium accelerate thrombus formation through effects on platelets and coagulation. Consequently, they are emerging as targets to inhibit thrombosis.

The main goal of this project is to better characterize the functional role of major PDIs in platelets and to reveal differences in regulation of platelet function and coagulation by PDIA1, PDIA3 and PDIA6 in atherosclerosis as compared with healthy conditions.

Obtained in this project knowledge will facilitate to develop future PDIs-targeting antithrombotic drugs, specific against atherothrombosis. On the other hand, a new perspective can open to use PDIs profiling as a tool to assess the severity of atherosclerosis or predict risk of thrombotic events due to progression of atherosclerosis.

SONATA 17 for the prevention of pro-thrombotic conditions in atherosclerosis